Back to Schroder Investment Management Group Schroder Investment Management Group

FATE

14 quarters

Position history for Schroder Investment Management GroupSchroder Investment Management Group's holdings in Fate Therapeutics, Inc.

No. Schroder Investment Management Group exited its FATE (Fate Therapeutics) position in Q1 2023. Its Q4 2022 13F listed 137,341 shares worth $1.4M. Schroder Investment Management Group first reported FATE in Q4 2019 and held it in 13 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$1.8M

Total Shares Change

-92,503

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2023-Q1
Latest
Exited
0
-100.0%
$00.0%$5.70
0
2022-Q4
Increased
137,341
+3.6%
$1.4M0.0%$10.09
26
2022-Q3
Increased
132,552
+107.5%
$3M0.0%$22.41
43
2022-Q2
Increased
63,879
+1.6%
$1.6M0.0%$24.78
26
2022-Q1
Increased
62,881
+32.7%
$2.5M0.0%$38.77
33
2021-Q4
Increased
47,388
+46.1%
$2.8M0.0%$58.51
36
2021-Q3
Decreased
32,440
-45.2%
$1.9M0.0%$59.27
0
2021-Q2
Increased
59,234
+31.6%
$5.1M0.0%$86.79
34
2021-Q1
Decreased
45,008
-42.3%
$3.7M0.0%$82.45
0
2020-Q4
Decreased
77,951
-11.3%
$7.1M0.0%$90.93
0
2020-Q3
Increased
87,908
+9.3%
$3.3M0.0%$39.97
29
2020-Q2
Decreased
80,389
-13.6%
$2.8M0.0%$34.31
0
2020-Q1
Increased
93,003
+0.5%
$2.3M0.0%$22.21
26
2019-Q4
New
92,503
-
$1.8M0.0%$19.57
36

Other major holders of FATE: FMR LLC, ARK Investment Management LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used